Keynote address: Benjamin Hampstead
| Thursday, November 7, 2019 |
| 4:45 PM - 5:45 PM |
| Shiraz Room A & B |
Presentation
Shiraz Room A & B
Presenter(s)
Associate Professor Benjamin Hampstead
University of Michigan
Methods of enhancing cognition in older adults across the dementia spectrum
4:45 PM - 5:45 PMSummary
The impact of cognitive deficits associated with age-related neurologic injury and disease is becoming increasingly evident as the proportion of older adults increases worldwide. The failure of pharmacologic agents to arrest neurodegenerative diseases or substantially improve cognition leaves a vital gap in scientific knowledge and clinical services. Several lines of independent research suggest that non-pharmacologic interventions provide tools through which to maximize cognition in older adults. This session will specifically review cognitive and neurophysiological evidence of change arising from cognitively oriented treatments (e.g., cognitive rehabilitation, cognitive training) and non-invasive brain stimulation in older adults across the dementia spectrum. Particular attention will be paid to methodologic factors that are vital to clinical translation, such as clinical staging and dose-response relationships.
.....
Dr. Hampstead is a board-certified Clinical Neuropsychologist who earned his PhD in Clinical Psychology (Neuropsychology emphasis) from Drexel University. He is an Associate Professor of Psychiatry at the University of Michigan, Staff Neuropsychologist in the VA Ann Arbor Healthcare System, and Clinical Core Leader of the NIA funded Michigan Alzheimer’s Disease Research Center. Dr. Hampstead’s research focuses on non-pharmacologic approaches to maximize cognitive functioning in older adults across the dementia spectrum. Specifically, he uses cognitively oriented treatments and non-invasive brain stimulation to enhance cognition, typically within the context of a randomized controlled trial format. Dr. Hampstead integrates these techniques with functional and structural neuroimaging in order to predict treatment response, identify the neuroplastic changes following treatment, and plan/develop new interventions. Ongoing work integrates amyloid and tau positron emission tomography (PET) in order to better characterize participant characteristics associated with treatment response. He has maintained continuous federal funding for his work since earning his doctorate (13+ years), with most support from the Department of Veterans Affairs and National Institute on Aging.
